Ann: Appendix 4C - Quarterly Cash Flow-OSL.AX, page-9

i am new to this stock but i dont really understand all the negativity.
i get that the ce mark has been a long time coming but that is pretty standard in the novel biotech game.
this technology is exciting and the fact that it is already being used in vivo at royal north shore sydney by the very highly reputed radiation oncologists suggests it is a high potential product.
you have to understand that locally advanced pancreatic cancer is screaming out for an advance in treatment.
as a surgeon i have seen hiw oancreatic cancer still has an average 5 year survival rate of 20%, compared to 80-90% for breast and prostate cancer.
pancreatic cancer is less common but far more lethal.
this means that even a small survival benefit or symptomatic benefit of a few months with the new treatment will justify it being funded by governments.
the concept is similar to brachytherapy seed implants or the new lutetium psma boynd radiation treatment for advanced prostate cancer.
basically you deliver a high dose of lethal radiation to the cancer with minimal toxicity to surrounding normal healthy tissues.
keep the faith guys, when this treatment takes off it will be the next sirtex.
the company wouldnt issue a statement suggesting ce mark by the end of the year if there was not good evidence to support this from the ce mark correspondence.